Matthieu Roulleaux Dugage
@matthieurd.bsky.social
MD, MSc
Immuno-Oncology 🧬
Drug Development Department
@GustaveRoussy
Immuno-Oncology 🧬
Drug Development Department
@GustaveRoussy
Hello Bluesky !
Very glad to share our editorial in Annals of Oncology :
👉 IL-6 = primary resistance to IO (CD8+ T cell dysfunction, protumoral inflammation)
👉 IL-6 = Th17 polarisation of CD4+ T cells = Tox (upon aCTLA4 ++)
👉 IL-6(R) + IO = very few data
Edito : doi.org/10.1016/j.an...
Very glad to share our editorial in Annals of Oncology :
👉 IL-6 = primary resistance to IO (CD8+ T cell dysfunction, protumoral inflammation)
👉 IL-6 = Th17 polarisation of CD4+ T cells = Tox (upon aCTLA4 ++)
👉 IL-6(R) + IO = very few data
Edito : doi.org/10.1016/j.an...
doi.org
December 8, 2024 at 7:43 AM
Hello Bluesky !
Very glad to share our editorial in Annals of Oncology :
👉 IL-6 = primary resistance to IO (CD8+ T cell dysfunction, protumoral inflammation)
👉 IL-6 = Th17 polarisation of CD4+ T cells = Tox (upon aCTLA4 ++)
👉 IL-6(R) + IO = very few data
Edito : doi.org/10.1016/j.an...
Very glad to share our editorial in Annals of Oncology :
👉 IL-6 = primary resistance to IO (CD8+ T cell dysfunction, protumoral inflammation)
👉 IL-6 = Th17 polarisation of CD4+ T cells = Tox (upon aCTLA4 ++)
👉 IL-6(R) + IO = very few data
Edito : doi.org/10.1016/j.an...